Okay, let's tackle this question about the mechanism of resistance to penicillin via beta-lactamase. First, I need to recall the core concept here. Beta-lactam antibiotics like penicillin work by inhibiting cell wall synthesis in bacteria. The key point is how bacteria become resistant to these drugs.

Beta-lactamase is an enzyme that breaks down the beta-lactam ring of these antibiotics, rendering them ineffective. So the question is asking which option correctly identifies this mechanism. The correct answer should be that the bacteria produce beta-lactamase, which hydrolyzes the beta-lactam ring, thus preventing the antibiotic from binding to its target, the penicillin-binding proteins (PBPs).

Now, the wrong options might include other resistance mechanisms like mutation of PBPs, reduced drug permeability, or efflux pumps. Each of these is a different mechanism. For example, if an option says "mutation of penicillin-binding proteins," that's a different mechanism called target site modification. Another wrong option might be "inhibition of autolytic enzymes," which is not a recognized resistance pathway for beta-lactams.

The clinical pearl here is that beta-lactamase production is a common resistance mechanism in many Gram-positive and Gram-negative bacteria. It's important to remember that adding beta-lactamase inhibitors like clavulanic acid can restore the effectiveness of penicillins against such resistant strains.

So, putting this all together, the correct answer is the one that states the bacteria produce beta-lactamase, which hydrolyzes the beta-lactam ring. The other options are incorrect because they describe different resistance mechanisms. The clinical takeaway is the role of beta-lactamase inhibitors in overcoming this resistance.

**Core Concept**
Beta-lactam antibiotics inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Resistance via beta-lactamase involves enzymatic hydrolysis of the beta-lactam ring, inactivating the drug.

**Why the Correct Answer is Right**
Beta-lactamase is an enzyme produced by bacteria that catalyzes the hydrolysis of the beta-lactam ring in penicillin. This structural alteration prevents the antibiotic from binding to PBPs, which are essential for cross-linking peptidoglycan in the bacterial cell wall. Without PBP inhibition, bacteria can continue synthesizing their cell wall, surviving the antibiotic.

**Why Each Wrong Option is Incorrect**
**Option A:** Suggests "mutation of PBPs" (e.g., methicillin-resistant *Staphylococcus aureus* [MRSA]), which is a distinct mechanism called target site modification, not beta-lactamase activity.
**Option B:** Claims "reduced drug permeability," which is seen in Gram-negative organisms with impermeable outer membranes but does not involve beta-lactamase.
**Option C:** Proposes "efflux pumps," which actively expel the antibiotic but do not hydrolyze it.

**Clinical Pearl / High-Yield Fact**
Beta-lactamase production is a common resistance mechanism in *Staphylococcus aureus*, *Escherichia coli*, and *Klebsiella*. Combining beta-lactam antibiotics with beta-lactamase inhibitors (e.g., amoxicillin-cl

✓ Correct Answer: C. BREAKS DRUG STRUCTURE